151 related articles for article (PubMed ID: 2190320)
1. Oral iron chelators.
Nathan DG; Piomelli S
Semin Hematol; 1990 Apr; 27(2):83-5. PubMed ID: 2190320
[No Abstract] [Full Text] [Related]
2. Current status of iron chelation therapy with deferoxamine.
Cohen A
Semin Hematol; 1990 Apr; 27(2):86-90. PubMed ID: 2190321
[TBL] [Abstract][Full Text] [Related]
3. Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.
Olivieri NF; Koren G; St Louis P; Freedman MH; McClelland RA; Templeton DM
Semin Hematol; 1990 Apr; 27(2):101-4. PubMed ID: 2190316
[No Abstract] [Full Text] [Related]
4. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
5. High-dose intravenous chelation therapy with deferoxamine.
Cohen A; Mizanin J; Schwartz E
Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
[No Abstract] [Full Text] [Related]
6. Iron chelation.
Hershko C; Link G; Pinson A
Prog Clin Biol Res; 1989; 309():133-40. PubMed ID: 2675082
[No Abstract] [Full Text] [Related]
7. Iron chelation.
Chandy M
J Assoc Physicians India; 1991 Sep; 39(9):665-6. PubMed ID: 1814896
[No Abstract] [Full Text] [Related]
8. Oral iron chelators.
Semin Hematol; 1990 Apr; 27(2):83-120. PubMed ID: 2349485
[No Abstract] [Full Text] [Related]
9. Current recommendations for chelation for transfusion-dependent thalassemia.
Kwiatkowski JL
Ann N Y Acad Sci; 2016 Mar; 1368(1):107-14. PubMed ID: 27186943
[TBL] [Abstract][Full Text] [Related]
10. Compliance with therapy in Cooley's anaemia.
Vullo C; Di Palma A
Prog Clin Biol Res; 1989; 309():43-9. PubMed ID: 2780749
[No Abstract] [Full Text] [Related]
11. Iron chelating therapy in thalassemia: current problems.
Russo G
Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
[No Abstract] [Full Text] [Related]
12. Medical management of beta-thalassemia.
Lerner N
Prog Clin Biol Res; 1989; 309():13-22. PubMed ID: 2780747
[No Abstract] [Full Text] [Related]
13. Principles of iron chelating therapy.
Hershko C; Link G; Pinson A
Semin Hematol; 1990 Apr; 27(2):91-4. PubMed ID: 2190322
[No Abstract] [Full Text] [Related]
14. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
Borgna-Pignatti C; Rugolotto S; De Stefano P; Zhao H; Cappellini MD; Del Vecchio GC; Romeo MA; Forni GL; Gamberini MR; Ghilardi R; Piga A; Cnaan A
Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202
[TBL] [Abstract][Full Text] [Related]
15. Iron metabolism and iron chelation in the thalassaemia disorders.
Pippard MJ
Haematologica; 1990; 75 Suppl 5():66-71. PubMed ID: 2086383
[No Abstract] [Full Text] [Related]
16. MRI and iron-overload cardiomyopathy in thalassaemia.
Pennell D
Circulation; 2006 Mar; 113(11):f43-4. PubMed ID: 16552847
[No Abstract] [Full Text] [Related]
17. Measurement of iron status.
Pippard MJ
Prog Clin Biol Res; 1989; 309():85-92. PubMed ID: 2675108
[No Abstract] [Full Text] [Related]
18. Clinical studies on iron chelation in patients with thalassemia major.
Freedman MH; Olivieri N; Benson L; Liu P; McClelland R; St Louis P; Templeton D; Koren G
Haematologica; 1990; 75 Suppl 5():74-83. PubMed ID: 2086384
[No Abstract] [Full Text] [Related]
19. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).
Di Tucci AA; Murru R; Alberti D; Rabault B; Deplano S; Angelucci E
Eur J Haematol; 2007 Jun; 78(6):540-2. PubMed ID: 17391307
[TBL] [Abstract][Full Text] [Related]
20. Hepatic iron stores in thalassemia: non-invasive magnetic measurements.
Brittenham GM; Allen CJ; Farrell DE; Harris JW
Prog Clin Biol Res; 1989; 309():101-6. PubMed ID: 2780744
[No Abstract] [Full Text] [Related]
[Next] [New Search]
